Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial

PURPOSE: The 24-week INTREPID trial demonstrated the clinical benefits of once-daily single-inhaler triple therapy (SITT) with fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) versus non-ELLIPTA multiple-inhaler triple therapy (MITT) in patients with symptomatic chronic obstructive pul...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpin, David M G, Kendall, Robyn, Shukla, Soham, Martin, Alan, Shah, Dhvani, Midwinter, Dawn, Beeh, Kai M, Kocks, Janwillem W H, Jones, Paul W, Compton, Chris, Risebrough, Nancy A, Ismaila, Afisi S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617516/
https://www.ncbi.nlm.nih.gov/pubmed/36317185
http://dx.doi.org/10.2147/COPD.S370577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9617516/
https://www.ncbi.nlm.nih.gov/pubmed/36317185
http://dx.doi.org/10.2147/COPD.S370577

Ejemplares similares